sitagliptin and Metabolic-Syndrome

sitagliptin has been researched along with Metabolic-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for sitagliptin and Metabolic-Syndrome

Article	Year
Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome. Bioorganic & medicinal chemistry letters, 2017, 06-01, Volume: 27, Issue:11 Designing drug candidates exhibiting polypharmacology is one of the strategies adopted by medicinal chemists to address multifactorial diseases. Metabolic disease is one such multifactorial disorder characterized by hyperglycaemia, hypertension and dyslipidaemia among others. In this paper we report a new class of molecular framework combining the pharmacophoric features of DPP4 inhibitors with those of ACE inhibitors to afford potent dual inhibitors of DPP4 and ACE. Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Humans; Inhibitory Concentration 50; Metabolic Syndrome; Mice; Microsomes, Liver; Molecular Docking Simulation; Rats	2017

Article

Year

Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome.

Bioorganic & medicinal chemistry letters, 2017, 06-01, Volume: 27, Issue:11

Designing drug candidates exhibiting polypharmacology is one of the strategies adopted by medicinal chemists to address multifactorial diseases. Metabolic disease is one such multifactorial disorder characterized by hyperglycaemia, hypertension and dyslipidaemia among others. In this paper we report a new class of molecular framework combining the pharmacophoric features of DPP4 inhibitors with those of ACE inhibitors to afford potent dual inhibitors of DPP4 and ACE.

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Humans; Inhibitory Concentration 50; Metabolic Syndrome; Mice; Microsomes, Liver; Molecular Docking Simulation; Rats

2017